pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,083 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1171Endpoints885BioPharma Dive340BioSpace304Fierce Biotech285onclive165raps104globenewswire health73
therapy area
allOncology7505Rare Disease1856Cardiology1708Immunology1472Hematology1313Vaccines1192Pulmonology
  • Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029
    Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. excha…
    Endpoints · 3mo agoDealPositive↗ source
  • J&J to acquire Firefly Bio for $1 billion, boosting its KRAS-focused antibody-degrader program
    Johnson & Johnson announced it will purchase Firefly Bio, a preclinical biotech, for $1 billion in cash. Firefly Bio is developing degrader antibody conjugates that aim to target KRAS-driven cance…
    Endpoints · 3mo agoDealPositive↗ source
← prev
page 61 of 84
next →
fda recalls67
fda medwatch60
fda press38
1127
Psychiatry & CNS864
Ophthalmology494
Pain478
Endocrinology & Metabolism468
Infectious Disease444
  • Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfront
    Incyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion. The acquisition gives Incyte control of…
    Endpoints · 3mo agoDealNeutral↗ source
  • City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt disease
    City Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategy
    Incyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…
    Endpoints · 3mo agoDealPositive↗ source
  • City Therapeutics raises $99.5 million to advance three RNAi drug candidates
    City Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing. The capital will be used to move its first…
    Endpoints · 3mo agoDealPositive↗ source
  • GoHealth files for Chapter 11 bankruptcy as Medicare Advantage insurers retreat
    GoHealth, a health‑insurance marketplace that serves seniors, voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court. The filing follows a period of volatility in the Medicare Ad…
    Endpoints · 3mo agoNegative↗ source
  • Tango Therapeutics reports strong early response with vopimetostat plus daraxonrasib in pancreatic cancer trial
    Tango Therapeutics announced that its experimental epigenetic drug vopimetostat, when combined with Revolution Medicines' KRAS inhibitor daraxonrasib, produced high response rates in a small pancre…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • GSK partners with Engitix on multi-target liver research
    GSK announced a collaboration with London-based Engitix to explore multiple targets for liver disease. Engitix will apply its extracellular matrix-based disease models to uncover new therapeutic op…
    Endpoints · 3mo agoDealNeutral↗ source
  • Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidates
    Cavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…
    Endpoints · 3mo agoDealPositive↗ source
  • Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appeal
    Takeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Biopharma must pair innovation with operational readiness to scale therapies
    The article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable pro…
    BioPharma Dive · 3mo agoNeutral↗ source
  • Novo Nordisk aims to bring triple-G obesity injection to market by 2030
    Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…
    Endpoints · 3mo agoPositive↗ source
  • Logistics firms tackle time-critical delivery of radiopharmaceuticals for cancer care
    Radiopharmaceuticals are emerging as a key tool in oncology, offering cell‑level targeting that spares healthy tissue while delivering radiation directly to tumors. Because the radioactive isotope…
    BioPharma Dive · 3mo agoPositive↗ source
  • Endpoints News identifies 25 biopharma CEOs earning $25M or more in 2025
    Endpoints News released a ranking of the highest-paid chief executives in the biopharma sector for 2025. For the first time in four years the publication raised the minimum compensation threshold…
    Endpoints · 3mo agoNeutral↗ source
  • Biopharma pay series to return with new installments
    The publisher announced that new installments of its biopharma pay series will be released in the near future. The series traditionally examines compensation trends and salary data across the phar…
    Endpoints · 3mo agoNeutral↗ source
  • Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effects
    Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early data
    Pfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesity
    Roche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide. The company describes petrelintide as having a potentiall…
    Endpoints · 3mo agoCRLPositive↗ source
  • Lawmakers propose China restrictions and ASCO 2026 highlights
    The latest Endpoints Weekly notes that U.S. lawmakers are introducing new measures aimed at limiting certain activities with China, though details were not disclosed in the brief. The issue also r…
    Endpoints · 3mo agoNeutral↗ source
  • Lundbeck advances PACAP-targeting migraine drug after mid-stage trial shows reduction in migraine days
    Lundbeck reported new data from a mid-stage study of its experimental migraine prevention therapy, bocunebart, which targets the PACAP protein involved in headache pathways. The trial enrolled hun…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Roche's daily incretin injection shows promise in Phase 2 trial for type 1 diabetes
    Roche reported that its experimental daily incretin injection achieved positive results in a Phase 2 study involving patients with type 1 diabetes. The study, the first mid-stage trial of a GLP-1…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Supreme Court rules generic Vascepa copy does not infringe patents, boosting skinny-label pathway
    The U.S. Supreme Court issued a decision that Hikma Pharmaceuticals’ generic version of Amarin’s heart drug Vascepa does not infringe the brand’s patents. The ruling clarified that the generic make…
    BioPharma Dive · 3mo agoRegulatoryPositive↗ source
  • Innovent Biologics reports Phase 3 success for stomach cancer ADC, now under priority review in China
    Innovent Biologics announced that its antibody‑drug conjugate (ADC) candidate has met the primary endpoint in a Phase 3 trial for advanced stomach cancer. The positive outcome has placed the produ…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Fulcrum Therapeutics cuts workforce, retaining only nine employees as layoffs hit 48 staff
    Fulcrum Therapeutics announced a dramatic reduction in its staff, letting go of 48 of its 57 full‑time employees. The move leaves the company with just nine remaining workers, effectively turning i…
    Endpoints · 3mo agoLayoffsNegative↗ source